phenazopyridine hydrochloride(redirected from ReAzo)
Pharmacologic class: Nonopioid analgesic
Therapeutic class: Urinary analgesic
Pregnancy risk category B
Unknown. Thought to act locally on urinary tract mucosa to produce analgesic or anesthetic effects, relieving urinary burning, urgency, and frequency.
Tablets: 95 mg, 97.2 mg, 100 mg, 200 mg
Indications and dosages
➣ Pain caused by lower urinary tract irritation
Adults: 200 mg P.O. t.i.d.
Children: 12 mg/kg P.O. daily in three divided doses
• Hypersensitivity to drug
• Renal insufficiency
Use cautiously in:
• pregnant or breastfeeding patients
• children younger than age 12.
• Give with or after meals.
• Discontinue after 2 days, as prescribed, when administering with antibiotics.
EENT: contact lens staining
GI: GI disturbances
GU: bright orange urine, renal toxicity
Hematologic: hemolytic anemia,
Skin: rash, pruritus
Other: anaphylactoid-like reaction
Drug-diagnostic tests. Bilirubin, glucose, ketones, protein, steroids: interference with urine tests based on spectrophotometry or color reactions
• Monitor patient for symptomatic improvement of urinary tract infection (UTI).
• Assess follow-up urine culture after antibiotic therapy ends.
☞ Monitor for yellowing of skin or sclera. This change may indicate drug accumulation caused by impaired renal excretion, warranting drug withdrawal.
• Explain drug therapy and measures to help prevent UTI recurrence.
• Tell patient drug may discolor urine and tears and may stain clothing and contact lenses.
☞ Advise patient to contact pre-scriber promptly if symptoms don't improve or if skin or eyes become yellow.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.